Trial Outcomes & Findings for Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer (NCT NCT01851174)

Results Overview

Determine the toxicity profile (decrease in hematological and non-hematological treatment-related AE's) with bi-weekly dosing of gemcitabine plus nab-Paclitaxel

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

15 participants

Primary outcome timeframe

One year

Results posted on

2018-02-07

Participant Flow

Participant milestones

Participant milestones
Measure	Gemcitabine and Nab-Paclitaxel Gemcitabine (1,000 mg/m\^2) administered intravenously on days 1 and 15, every 28 days nab-Paclitaxel (125 mg/m\^2) administered intravenously on days 1 and 15, every 28 days Gemcitabine: Patients will receive Gemcitabine (1,000 mg/m\^2) IV over 30 minutes after nab-paclitaxel infusion nab-Paclitaxel: Patients will receive nab-Paclitaxel (125 mg/m\^2) IV over 30 minutes before Gemcitabine infusion
Overall Study STARTED	15
Overall Study COMPLETED	15
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: One year

Population: The information required here was not captured. The investigator(s) are no longer at the site and no additional information or instruction was left.

Determine the toxicity profile (decrease in hematological and non-hematological treatment-related AE's) with bi-weekly dosing of gemcitabine plus nab-Paclitaxel

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: One year

Population: The information required here was not captured. The investigator(s) are no longer at the site and no additional information or instruction was left. Data were not collected

Determine progression free survival time with this regimen

Outcome measures

Outcome data not reported

Adverse Events

Gemcitabine and Nab-Paclitaxel

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jessica L. Coats

CTCA

Phone: 6232073899

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place